17 May 2023 | News
Early adopters for the Target and Lead Identification Suite include multinational pharmaceutical companies like Pfizer, and industry leading biotech companies like Cerevel
image credit- shutterstock
Google Cloud has announced two new artificial intelligence (AI)-powered life sciences solutions to accelerate drug discovery and precision medicine for biotech companies, pharmaceutical firms, and public sector organisations.
Available worldwide today, the Target and Lead Identification Suite helps researchers better identify the function of amino acids and predict the structure of proteins; and the Multiomics Suite accelerates the discovery and interpretation of genomic data, helping companies design precision treatments.
Google Cloud's Target and Lead Identification Suite enables biopharma companies to bring therapeutics to market faster by enabling more efficient in silico drug design. Its target identification will help companies quickly predict antibody structures, assess the structure and function of amino acid mutagenesis, and accelerate de novo protein design. This solution also enables lead optimisation that can be used to discover novel, high-quality candidates at low cost for Quantitative Structure Activity Relationship (QSAR) studies or for Free Energy Perturbation (FEP) calculations.
In addition, Google Cloud's Multiomics Suite advances precision medicine care by transforming multiomics data into insights to advance scientific discoveries.